Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Bone Right
  3. Forteo (teriparatide injection) Right
  4. Can pregnant or nursing women be treated with FORTEO® (teriparatide injection)?
Search Forteo (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Forteo ® (teriparatide injection)

20-mcg daily dose in a 2.4-mL prefilled delivery device

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Can pregnant or nursing women be treated with FORTEO® (teriparatide injection)?

Consider discontinuing teriparatide when pregnancy is recognized. Avoid teriparatide use in women who are breastfeeding.

US_cFAQ_TER014_PREGNANCY_DURING_AND_AFTER
US_cFAQ_TER014_PREGNANCY_DURING_AND_AFTER
en-US

Pregnancy During Teriparatide Treatment

There are no available data on teriparatide use in pregnant women to evaluate for drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Consider discontinuing teriparatide when pregnancy is recognized.1

Animal Studies

Based on animal studies, use during pregnancy may cause fetal harm.1

Pregnant mice received teriparatide during organogenesis at subcutaneous doses 8 to 267 times the human dose. At doses ≥60 times the human dose, the fetuses showed an increased incidence of skeletal deviations or variations, such as interrupted rib, extra vertebra, or extra rib.1

When pregnant rats received teriparatide during organogenesis at subcutaneous doses 16 to 540 times the human dose, the fetuses showed no abnormal findings.1

Nursing During Teriparatide Treatment

It is not known whether teriparatide is excreted in human milk, affects human milk production, or has effects on the breastfed infant.1

Avoid teriparatide use in women who are breastfeeding.1

Animal Studies

In a perinatal/postnatal study, pregnant rats received subcutaneous teriparatide from organogenesis through birth of the offspring and continued to receive teriparatide through lactation.1

Pregnant rats that were dosed subcutaneously from organogenesis through lactation experienced

  • mild growth retardation in female offspring at doses ≥120 times the human dose
  • mild growth retardation in male offspring at maternal doses 540 times the human dose, and
  • reduced motor activity in both male and female offspring at maternal doses 540 times the human dose.1

There were no developmental or reproductive effects in mice or rats at doses 8 or 16 times the human dose, respectively.1

Pregnancy After Teriparatide Treatment

Pregnancy outcomes in humans have not been studied after a full course of teriparatide treatment. Eli Lilly and Company has not followed patients after a course of therapy to successful pregnancy to determine an appropriate time frame once off the drug and before becoming pregnant.

Enclosed Prescribing Information

FORTEO® (teriparatide injection), Lilly

Reference

1Forteo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

Date of Last Review: October 18, 2022

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly